This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (26)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Immunotherapy  • Dermatology, Other  • Alert me on articles by topic

LCDR Ronald Buckley, MC, USN; COL Kathleen Smith, MC, USA
From the Department of Dermatology, Service Naval Hospital, Charleston, SC (Dr Buckley); and National Naval Medical Center, Bethesda, Md (Dr Smith)

Arch Dermatol. 1999;135:1167-1169.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

REPORT OF A CASE

A 32-year-old African American woman with human immunodeficiency virus 1 (HIV-1) and a 3-year history of extensive facial molluscum contagiosum (MCV) presented to the dermatology clinic for treatment. The patient had been treated with multiple therapies, including liquid nitrogen, topical 0.05% liquid tretinoin, and 0.5% topical podofilox, with no improvement and some secondary irritation to the latter 2 therapies.

At her initial appointment, she was taking nelfinavir mesylate (Viracept), 750 mg 3 times daily; stavudine (Zerit), 40 mg twice daily; didanosine (Videx), 200 mg twice daily; trimethoprim-sulfamethoxazole (Bactrim DS), 800 mg/160 mg every day; and fluconazole (Diflucan), 100 mg every day. She had been receiving nelfinavir, stavudine, and didanosine for 5 months and trimethoprim-sulfamethoxazole and fluconazole since shortly after her diagnosis 3 years earlier. Her CD4 T-cell count was 0.004x10⁹/L (38/mm³) and the viral load (Roche . . . [Full Text of this Article]

THERAPEUTIC CHALLENGE

SOLUTION

COMMENT

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients: Randomized, Double-blind, Placebo-Controlled Trial
Brown et al.
Arch Dermatol 2005;141:985-993.
ABSTRACT | FULL TEXT  

A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses
Stockfleth et al.
Arch Dermatol 2002;138:1498-1502.
ABSTRACT | FULL TEXT